ESTRO 36 Abstract Book

S746 ESTRO 36 2017 _______________________________________________________________________________________________

the 5-year LRR, DDR, DFS and OS were respectively: 3.4%, 13.2%, 84.5% and 92.1%. In the PMRT group, the 5-year LRR, DDR, DFS and OS were 4.5%, 14.1%, 85.9%, and 94.7%, respectively. In the non-PMRT group, the 5-year LRR, DDR, DFS and OS were 2.4%, 12.4%, 84.2% and 92.3%, respectively. In these small single center series, there was no difference in LRR, DDR, DFS and OS between the PMRT and non-PMRT group. There was no significant impact of comorbidity, T-stage, number of positive nodes, HR status, HER2 status and adjuvant chemotherapy on the effect of PMRT. Conclusion The benefit of PMRT might be limited in the unselected elderly patients with T1-2 and 1 to 3 positive nodes. The intensity of anti-cancer treatment including adjuvant chemotherapy and PMRT tends to decrease in patients with increased age at diagnosis. Larger study is needed to identify elderly patients with relative higher risk of LRR and metastasis, as well as the risk of toxicity to better individualize treatment. Clear biomarkers are needed to decide patients for whom radiotherapy can be avoided. EP-1411 Chemo-IMRT in elderly head and neck cancer patients I. Ahmed 1 , S. Kotur 1 , D. Sahoo 2 , D. Sougumarane 3 , R. Bhise 4 , K. Vinchurkar 5 , M. Kalloli 5 , A. Sanikoppa 6 1 Kle's belgaum cancer hospital, radiation oncology, Belgaum, India 2 Kle's belgaum cancer hospital, radiaiton oncology, Belgaum, India 3 kle's belgaum cancer hospital, radiation physics, Belgaum, India 4 Kle's belgaum cancer hospital, medical oncology, Belgaum, India 5 Kle's belgaum cancer hospital, surgical oncology, Belgaum, India 6 Kle's belgaum cancer hospital, pathology, belgaum,India Purpose or Objective Elderly patients have been underrepresented in prospective clinical trials that have defined standards of care for head and neck cancer. In the era of improved radiation techniques, improved systemic therapy and better supportive care can claim that chemoradiation does, in fact, improve survival for a large segment of this population and should not be denied for fear of poor tolerance. Material and Methods 21 patients with locally advanced head and neck cancer treated with SIB-IMRT and concurrent weekly cisplatin were prospectively evaluated. After written and informed consent, all patients were immobilised with head and neck thermoplastic mask followed by CT simulation. Critical structures and Planning Target volumes – high risk receiving 70Gy (PTVHR), intermediate risk receiving 63 or 59.4 Gy (PTVIR) and low risk receiving 56 or 54Gy (PTVLR) in 33-35 fractions over 6.5-7 weeks were defined and planned with Eclipse version 11 planning system using 7-9 field arrangements. Concurrent Chemotherapy was administered using weekly cisplatin 40mg/m2 or carboplatin AUC 2 for 6 cycles. All patients were evaluated for treatment compliance and radiation toxicities weekly. Outcomes were analysed in terms of clinical response evaluation using RECIST criteria, acute toxicities according to RTOG-EORTC and overall survival using Kaplan Meir curve. Results Median age of presentation was 69 years (range 65-76) with M: F ratio of 16:5. Primary site of presentation were hypopharynx (10), oropharynx (5) and larynx (6). TNM stage status were T1(2),T2(5), T3(11), T4(3); N1(4), N2(1), N3(1); Stage III(10), IVA(10) and IVB(1). All patients received 70 Gy. Median Overall treatment time was 53 days (range 46-65 days) with treatment interruption of 1- 9 days (median 3 days). All patients received 4-6 cycles of

cisplatin/carboplatin (median 6). Acute toxicities are shown in table. Mean weight loss was 8% (range 4- 15%).With a median follow up of 9 months (range 3-15 months), ORR were 71.5% (15 patients) had complete response and 28.5% (6 patients) had partial response. 7 (33%) patients had recurrence with 6 loco regional and 1 distant, out of which 3 expired and 4 are alive with disease. The overall 15 month survival rate is 75.6%. GRADE 1 GRADE 2 GRADE 3 GRADE 4 MUCOSITIS 1(5%) 17(80%) 3(14%) 0 DERMATITIS 17(80%) 3(14%) 1(5%) 0 LARYNGITIS 8(38%) 13(62%) 0 0 ANAEMIA 6(28%) 0 0 0 NEUTROPENIA 4(19%) 0 2(10%) 0 THROMBOCYTOPENIA 1(5%) 1(5%) 0 0

Conclusion Chemo-IMRT is feasible and well tolerated with acceptable outcomes even in the subset of elderly patients with locally advanced disease.

Electronic Poster: Clinical track: Other

EP-1412 Quality of life of patients after high dose radiation therapy for thoracic carcinomas C. Schröder 1 , R. Engenhart-Cabillic 2 , A. Buchali 3 1 Universität Giessen, Klinik für Strahlentherapie und Radioonkologie- Universitätsklinikum Giessen und Marburg, Giessen, Germany 2 Universität Marburg, Klinik für Strahlentherapie und Radioonkologie- Universitätsklinikum Giessen und Marburg, Marburg, Germany 3 Ruppiner Kliniken GmbH, Klinik für Strahlentherapie und Radioonkologie, Neuruppin, Germany Purpose or Objective Quality of life (QoL) is an important factor in patient care. In this analysis we focused on QoL before and after radio- (chemo-)therapy (RCT) in patients with thoracic carcinomas and its influence on clinical follow up, survival and the correlation with treatment related toxicities. Material and Methods 81 curatively treatable patients with intrathoracical carcinoma (NSCLC, SCLC, esophageal carcinoma) were included in this analysis. They received radio-(chemo-) therapy. Patients with NSCLC were treated with 74 Gy, patients with SCLC with 60 Gy and those with esophageal carcinomas with 66 Gy. Eligible patients received